

Cadila Healthcare Ltd. - Consolidated Gross Sales Break-up

Rs. Mio.	Q1 12-13	Q1 11-12	% Gr y-y
Domestic	7,454	5,946	25.4%
Formulations	5,818	4,574	27.2%
APIs	108	66	63.6%
Wellness	1,033	914	13.1%
Animal Health & Others	495	392	26.1%
Exports	6,718	4,817	39.5%
Formulations	5,952	4,136	43.9%
US	3,592	2,393	50.1%
Europe	854	769	11.1%
Japan	139	112	24.0%
Brazil	645	470	37.1%
Emerging Markets	721	392	84.0%
APIs	650	680	-4.5%
Animal Health & Others	116	0	
JVs	1295	1127	14.9%
Total	15,466	11,889	30.1%

Cadila Healthcare Ltd. - Details of other incomes

Rs. Mio.	Q1 12-13	Q1 11-12	% Gr y-y
Other Operating Income	783	722	8.4%
Dossier Fees	0	446	-100.0%
Royalty Income	156	52	200.0%
Net Gain on foreign currency transactions and translation (Refer Note below)	458	92	398.3%
Others	169	132	27.7%

Note : Apart from this gain, there was a loss of Rs. 421 Mio. on hedging, which has been included in Cost of Goods. Thus, on aggregate level, there was a gain of Rs. 37 Mio. on operating transactions (above EBIDTA line) in Q1 12-13 vs gain of Rs. 92 Mio. in Q1 11-12. See details below for more clarity.

Rs. Mio.	Q1 12-13	Q1 11-12	% Gr y-y
Other Income	95	63	51.0%
Interest & Dividend income	68	39	74.8%
Profit on sale of investments	1	1	25.7%
Profit on sale of assets	9	21	-56.9%
Others	17	2	732.5%

Details of Foreign Exchange Fluctuations

Rs. Mio. (+ = loss, - = gain)	Q1 12-13	Q1 11-12	% Gr y-y
A. On operating transactions (above EBIDTA line)	-37	-92	59.3%
a. Included in other income	-458	-92	-398.3%
b. Included in cost of goods (hedging loss / gain)	421		
c. Included in other expenses			
B. On Foreign Currency Borrowings (part of interest cost)	153	-63	342.9%
Total Foreign Currency Fluctuations (+ = loss, - = gain)	116	-155	174.5%

Details of R&D Expenses

Rs. Mio.	Q1 12-13	Q1 11-12	% Gr y-y
Total R&D Expenses	873	785	11%

Consolidated Capex for Q1 12-13

**Rs. 2020
Mio.**

R&D capex included in above for Q1 12-13 :

**Rs. 196
Mio.**